We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The role of IL-6 in coronavirus, especially in COVID-19.
- Authors
Xinyi Wang; Guozheng Tang; Yuchen Liu; Lizhi Zhang; Bangjie Chen; Yanxun Han; Ziyue Fu; Liuning Wang; Guangzhi Hu; Qing Ma; Shuyan Sheng; Jianpeng Wang; Xinyang Hu; Song Shao
- Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects both people and animals and may cause significant respiratory problems, including lung illness: Corona Virus Disease 2019 (COVID-19). Swabs taken from the throat and nose of people who have the illness or are suspected of having it have shown this pathogenic virus. When SARS-CoV-2 infects the upper and lower respiratory tracts, it may induce moderate to severe respiratory symptoms, as well as the release of pro-inflammatory cytokines including interleukin 6 (IL-6). COVID-19-induced reduction of IL-6 in an inflammatory state may have a hitherto undiscovered therapeutic impact. Many inflammatory disorders, including viral infections, has been found to be regulated by IL-6. In individuals with COVID-19, one of the primary inflammatory agents that causes inflammatory storm is IL-6. It promotes the inflammatory response of virus infection, including the virus infection caused by SARS-CoV-2, and provides a new diagnostic and therapeutic strategy. In this review article, we highlighted the functions of IL-6 in the coronavirus, especially in COVID-19, showing that IL-6 activation plays an important function in the progression of coronavirus and is a rational therapeutic goal for inflammation aimed at coronavirus.
- Subjects
CORONAVIRUSES; SARS-CoV-2; PLANT viruses; INTERLEUKIN-6; VIRUS diseases
- Publication
Frontiers in Pharmacology, 2022, Vol 13, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2022.1033674